StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals SBC expense by award type

SBC expense by award type — Employee stock purchase plan (ESPP) ($M) ($M)

Vertex Pharmaceuticals SBC expense by award type: $27M in FY2025, up 48.4% from a year earlier.

Latest, FY2025
27
Period ended Dec 31, 2025
Change on a year earlier
+48.4%
18.2 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Note (Stock-based Compensation).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSBC expense by award type — Employee stock purchase plan (ESPP) ($M) ($M)Year on yearSource
FY2025Dec 31, 202527+48.4%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202418.2+15.2%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 202315.8-5.4%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 202216.7-31.6%Form 10-K (filed 2025-02-13) ↗
FY2021Dec 31, 202124.4+87.7%Form 10-K (filed 2024-02-15) ↗
FY2020Dec 31, 202013–Form 10-K (filed 2023-02-10) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals SBC expense by award type ($M), annual FY2020–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-by-type-espp

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.